Table 2 Univariate and multivariate Cox analyses of prognosis

Age: Over 70 vs. Below 70

0.52

0.25–1.13

0.1

Sex: Male vs. Female

1.00

0.48–2.08

0.99

Stage: IV + Recurrence vs. III

2.21

1.03–4.71

0.04

ECOG PS: 2 + 1 vs. 0

2.72

1.29–5.70

0.008

Pancreatic tumor location: Head vs. Others

0.94

0.46–1.90

0.86

CA19-9 (cut-off: 10,000 U/mL): CA19-9^high vs. CA19-9^low

1.77

0.75–4.15

0.19

CRP level (cut-off: 1.0 mg/dL): CRP^high vs. CRP^low

2.49

1.14–5.42

0.02

Histology: Poorly differentiated vs. Others

1.09

0.52–2.27

0.82

Second line therapy: Yes vs. No

0.61

0.30–1.24

0.17

CEC level (cut-off: 166 cells/4 mL): CEC^high vs. CEC^low

5.18

2.23–12.03

<0.001

IL-6 (cut-off: 19.3 pg/mL): IL-6^high vs. IL-6^low

2.52

0.73–8.64

0.14

IL-8 (cut-off: 11.3 pg/mL): IL-8^high vs. IL-8^low

1.74

0.82–3.67

0.15

IL-10 (cut-off: 7.82 pg/mL): IL-10^high vs. IL-10^low

5.05

1.55–16.39

0.007

VEGF (cut-off: 44.1 pg/mL): VEGF^high vs. VEGF^low

1.22

0.60–2.47

0.59

PDGF-BB (cut-off: 1127.5 pg/mL): PDGF-BB^high vs. PDGF-BB^low

0.93

0.43–2.04

0.86

HGF (cut-off: 471.3 pg/mL): HGF^high vs. HGF^low

2.52

1.22–5.21

0.01

SDF-1 alpha (cut-off: 110.6 pg/mL): SDF-1 alpha^high vs. SDF-1 alpha^low

1.23

0.60–2.53

0.56

Multivariate analysis

HR

95% CI

P

Stage: IV + Recurrence vs. III

2.04

0.78–5.35

0.15

ECOG PS: 2 + 1 vs. 0

2.58

0.98–6.76

>0.05

CRP level (cut-off: 1.0 mg/dL): CRP^high vs. CRP^low

2.04

0.62–6.76

0.24

CEC level (cut-off: 166 cells/4 mL): CEC^high vs. CEC^low

5.14

1.83–14.45

0.002

IL-10 (cut-off: 7.82 pg/mL): IL-10^high vs. IL-10^low

5.26

1.26–22.22

0.02

HGF (cut-off: 471.3 pg/mL): HGF^high vs. HGF^low

1.34

0.46–3.91

0.59